CD274 molecule

Where the papers sit

93 papers from the last 6 months study CD274 molecule directly · updated from PubMed 12 Oct 2026

• PD-1 Resistance and Resensitization

  PD-1/PD-L1 therapy is moving toward rational combinations that restore responses in resistant tumors. Recurrent strategies target PDK4/GLS metabolism, XIAP-coordinated PKC signaling, STING-driven suppression and epigenetic regulation, alongside new small molecules and nanomedicines. Natural products, vaccines and artificial antigen-presenting cells aim to strengthen CD8-positive and interferon-linked immunity. The main open question is which resistance mechanism best predicts benefit from rechallenge or combination therapy.

  25 papers · 26.9%

• Anti-PD-L1 Combination Therapy

  Anti-PD-L1 therapy is being redesigned through tumor-selective delivery, enzymatic activation and combinations that remodel the immune microenvironment. Desialylation, lactylation and the NAT1-ENO1-lactate axis recur as ways to destabilize or improve the function of PD-L1. Nanoparticles, engineered probiotics, fusion proteins and CD28 siRNA address extracellular-vesicle barriers and anti-PD-1 resistance. Molecular imaging with radiolabeled atezolizumab and related tracers is moving PD-L1 assessment toward treatment selection.

  15 papers · 16.1%

• Tumor Immune Evasion

  PD-L1-driven immune evasion is being connected to oncogenic signaling, metabolism and tumor–host interactions, with triple-negative breast cancer as a major focus. The AR/ARD1/DLGAP5 and AKT/mTOR/c-Myc axes recur as drivers of progression, while microbiota, glycosylation and extracellular vesicles provide additional therapeutic entry points. Durvalumab-based treatment, integrin blockade and chemoimmunotherapy favor combination strategies over checkpoint inhibition alone. Molecularly selected approaches remain needed across the different tumor types represented.

  14 papers · 15.1%

• PD-L1 Therapy in Lung Cancer

  Lung cancer treatment is advancing from single-agent PD-1 blockade toward perioperative, radiation-based and antibody-drug conjugate combinations. Pembrolizumab and nivolumab studies focus on first-line benefit, neoadjuvant activity and adjuvant relapse prevention, while sacituzumab tirumotecan is being tested against pembrolizumab alone. PD-L1 scoring, tumor inflammation, CT imaging and extracellular-vesicle assays are being developed as response biomarkers. EGFR context and TGFβ-linked hyperprogression remain important sources of resistance and treatment uncertainty.

  11 papers · 11.8%

• Tumor Immunity and Checkpoint Blockade

  Checkpoint blockade is being paired with tumor-microenvironment interventions rather than used alone. Recurring targets include PD-L1 glycosylation, tumor-associated macrophages, CTGF-positive fibroblasts, CXCL13 inflammation and SRSF2-dependent immune evasion. CTLA-4 and PD-L1 therapies remain central, but regulatory T-cell expansion may create resistance. Immune-related myasthenia gravis and myocarditis underscore the need to balance efficacy with severe toxicity.

  10 papers · 10.8%

• Multivalent Protein Therapeutics

  Targeted protein therapeutics are shifting toward modular molecules that combine recognition, degradation, imaging and payload delivery. Multivalent degraders, degrader-drug conjugates, tetravalent multispecific antibodies and platelet-based lysosome-targeting systems recur across the engineering work. AI-designed minibinders and cyclic peptides extend this approach to difficult cancer cell-surface proteins, while PD-L1 radioligands link diagnosis with precision theranostics. The field is emphasizing plug-and-play assembly and quantitative validation, although clinical benefit remains less established than molecular performance.

  9 papers · 9.7%

• PD-L1 in Squamous Cell Carcinoma

  PD-L1 heterogeneity and systemic immune state are becoming central to response prediction in head, neck, oral and related squamous cell carcinomas. Spatial expression of PD-L1 and c-MET, plasma cytokines and myeloid remodeling are being paired with clinical outcomes to refine patient selection. Pembrolizumab with chemoradiotherapy and neoadjuvant PD-L1 blockade exemplify movement toward response-guided treatment. Mechanistic studies highlight GMPS-USP7 deubiquitination, hypoxia-linked lncRNA programs and CDK4/6-sensitive immune subtypes as potential intervention points.

  9 papers · 9.7%